Alzheimer's disease drug development pipeline: 2017

2017539 citationsReviewgold Open Access

Authors

Travis Mortsdorf · Touro University Nevada

Kate Zhong · Global Alzheimer's Platform Foundation

Abstract

The AD drug development pipeline has 105 agents divided among phase I, phase II, and phase III. The trials include a wide range of clinical trial populations, many mechanisms of action, and require a substantial number of clinical trial participants. Biomarkers are increasingly used in patient identification and as outcome measures, particularly in trials of DMTs.

Topics & Keywords

Computational Drug Discovery Methods Cholinesterase and Neurodegenerative Diseases Alzheimer's disease research and treatments

Publication Details

Published in: Alzheimer s & Dementia Translational Research & Clinical Interventions

Volume 3, Issue 3, pp. 367-384

DOI: 10.1016/j.trci.2017.05.002

Field-Weighted Citation Impact: 59.95

Command Palette

Alzheimer's disease drug development pipeline: 2017

Authors

Abstract

Topics & Keywords

Publication Details